Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 6/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215045 | 0.90 | TNKS (0.60) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL13351356 | 0.88 | TNKS (0.51) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL23952719 | 0.87 | TNKS (0.55) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL6161469 | 0.84 | TNKS (0.55) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL18425302 | 0.84 | CYP3A4 (0.53) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL12372559 | 0.84 | TNKS (0.51) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL12403053 | 0.84 | DRD2 (0.56) | DRD2KCNH2TNKSTNKS2CHRM1 | |
| SCHEMBL16455972 | 0.83 | TNKS (0.57) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| SCHEMBL16456311 | 0.83 | TNKS (0.57) | DRD2KCNH2TNKSTNKS2CHRM2 | |
| Bromide SCHEMBL1197758 | 0.83 | TNKS (0.54) | DRD2KCNH2TNKSTNKS2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039694-B1 | CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20100298303-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7452903-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070225272-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-09-27 | — | — | US | disclosed |
| US-7235545-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111204-A1 | Methods for detecting nucleic acid variations | POLN, LIG4, NCL | DRD2 4688/4885KCNH2 3277/4885TNKS 1366/4885 |
| US-20100298303-A1 | CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB1, BDKRB2 | DRD2 565/4885KCNH2 126/4885TNKS 2402/4885 |
| US-20070225272-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | DRD2 565/4885KCNH2 126/4885TNKS 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.